The use of guideline-recommended drugs in the 2016–2018 registry study, such as antiplatelet agents, β-blockers, and statins, was greater than that in a national study in 2014–2015, which reported that an increasing trend was maintained until 2018 in central China.
← all excerpts
Changes in process and outcome for ST elevation myocardial infarction in central China from 2011 to 2018.
1
—
—